https://www.selleckchem.com/pr....oducts/phycocyanobil
We enjoyed the article by Kitajima et al.(1) describing living donor liver transplantation (LDLT) for patients with a combination of a mid-Model for End-Stage Liver Disease (MELD) score and ascites. These patients had significantly increased hazards for mortality than patients undergoing deceased donor liver transplantation (DDLT). However, left lobe living donor graft could be a good choice in terms of appropriate donor-recipient combinations for an elective LDLT surgery.Major pathogenesis and signaling underlying cell-autonomo
Like
Comment
Share
